eclipse
surgical
technologies
said
friday
promising
follow
results
randomized
phase
ii
clinical
trial
transmyocardial
revascularization
tmr
treatment
patients
angina
severe
heart
disease.the
company
said
data
form
basis
pre
market
approval
application
food
drug
administration
later
summer
asix
month
follow
completed.eclipse
medical
device
company
specializing
cardiac
revascularization
products
treatment
advanced
cardiovascular
disease
